ANRO Stock Forecast: Alto Neuroscience, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Alto Neuroscience, Inc. hold a median 12-month price target of $37 — +45.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 57 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Alto Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ANRO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ANRO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +45.8% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | BTIG | Reiterates | Buy | $37 |
| 19 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $55 → $60 |
| 17 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $55 |
| 13 Aug 2026 | BTIG | Maintains | Buy | $28 → $37 |
| 13 Aug 2026 | Wedbush | Maintains | Neutral | $24 → $26 |
| 18 May 2026 | Baird | Maintains | Outperform | $38 → $36 |
| 14 May 2026 | Wedbush | Maintains | Neutral | $21 → $24 |
| 11 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 11 May 2026 | HC Wainwright& Co. | Reiterates | Buy | — |
| 22 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Apr 2026 | Baird | Maintains | Outperform | — |
| 2 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2026 | Jones Trading | Maintains | Buy | — |
| 2 Apr 2026 | Wedbush | Maintains | Neutral | — |
| 18 Mar 2026 | Baird | Maintains | Outperform | — |
| 17 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Neutral | — |
| 17 Feb 2026 | BTIG | Maintains | Buy | — |
| 5 Jan 2026 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ANRO.
This page is one stock. Monday covers all of them.
ANRO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ANRO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Alto Neuroscience, Inc. returned +79.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ANRO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 3.4×
- EV / EBITDA
- —
Cheaper than 27% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −46.6%
- Return on assets
- −26.5%
- Dividend yield
- —
Higher than 22% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alto Neuroscience, Inc. has a market value of $1.0B and an enterprise value of $716.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$84.2M.
Free cash flow in the twelve months to 30 June 2026: −$68.8M, after $556K of capital spending.
Alto Neuroscience, Inc. employs 68 people.
Data provided by Twelve Data
ANRO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ANRO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Alto Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ANRO
What is the ANRO stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Alto Neuroscience, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ANRO stock a buy right now?
Of the 11 analysts covering Alto Neuroscience, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alto Neuroscience, Inc. 57 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ANRO?
As at 21 Nov 2026, Alto Neuroscience, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
Will ANRO stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +45.8% from the last close, and Ticker Nerd's factor model ranks Alto Neuroscience, Inc. 57 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ANRO stock forecast for 2030?
No analyst covering Alto Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $60 over the next 12 months.
How has ANRO stock performed over the past year?
Alto Neuroscience, Inc. returned +79.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alto Neuroscience, Inc. do?
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit.
About Alto Neuroscience, Inc.
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit. Its current pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and related cognitive and mood disorders. The company is centered on personalized psychiatry, using biology-driven research to support the development of novel psychiatric treatments. Alto Neuroscience is headquartered in Mountain View, California, and its work today is concentrated on advancing clinical-stage programs for mental health conditions through biomarker-guided drug development.
CEO Dr. Amit Etkin M.D., Ph.D. · 68 employees · United States · https://www.altoneuroscience.com